Iovance Biotherapeutics rides high after FDA grants Breakthrough Therapy designation for its cervical cancer treatment

08:05 EDT 23 May 2019 | Proactive Investors

Meanwhile, Baird reiterated its Outperform rating and $34 price target on the shares

More From BioPortfolio on "Iovance Biotherapeutics rides high after FDA grants Breakthrough Therapy designation for its cervical cancer treatment"